Report
Adam Fleck
EUR 850.00 For Business Accounts Only

Morningstar | Higher Expenses the Backdrop to Disappointing Mayne Pharma Result

Through a series of acquisitions, Mayne Pharma has transformed into a vertically integrated specialty drug manufacturer with proprietary drug delivery expertise and a substantial product portfolio. The company’s stated strategy is heavily geared towards the timely introduction of enhanced generic formulations targeting niche markets, primarily in the U.S., which has been significantly expanded with the Teva generic portfolio acquisition. In the medium term, the company aims to win significant market share that is less vulnerable to price erosion, while Mayne's vertical integration strategy promises synergy gains through cross-selling opportunities across multiple geographies. Uncertainty in the timing of new product approvals provides impetus for ongoing brand acquisitions in order to build scale, but also increases the risk of dilution to existing shareholders.
Underlying
Mayne Pharma Group Limited

Mayne Pharma is a pharmaceutical company focused on applying its drug delivery capabilities to commercialize branded and generic pharmaceuticals. Co. operates in four business units: Generic Products, which develops, manufactures, markets and distributes generic pharmaceutical products in the U.S.; Specialty Brands, which markets and distributes specialty branded pharmaceutical products in the U.S.; Metrics Contract Services, which provides contract pharmaceuticals development services and analytical services to third parties; and Mayne Pharma International, which develops, manufactures, markets and distributes branded and generic pharmaceutical products globally, excluding the U.S.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Adam Fleck

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch